- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06559306
주요 우울증 장애 및 불면증 증상이 있는 성인 및 노인 참가자에 대한 셀토렉산트의 보조 치료에 대한 3상 연구
불면증 증상을 동반한 주요 우울증 장애가 있는 성인 및 노인 환자의 항우울제에 대한 보조 요법으로서 20mg 셀토렉산트의 유효성과 안전성, 효과 유지를 평가하기 위한 2부분으로 구성된 다기관, 이중 맹검, 무작위 위약 대조 연구
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Bucharest, 루마니아, 041914
- 모병
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia
-
Bucharest, 루마니아, 041914
- 완전한
- Spitalul Clinic de Psihiatrie Prof Dr Alexandru Obregia 2
-
Cluj-Napoca, 루마니아, 400012
- 완전한
- Spitalul Clinic Judetean de Urgenta Cluj Napoca
-
Cluj-Napoca, 루마니아, 400012
- 완전한
- Spitalul Clinic Judetean de Urgenta Cluj Napoca 1
-
Craiova, 루마니아, 200157
- 모병
- Centrul Medical Melchisedec
-
Focşani, 루마니아, 620117
- 완전한
- CMI Dr. Sarpe Marcel-Claudiu
-
Iași, 루마니아, 700282
- 완전한
- Institutului Regional de Psihiatrie 'Socola' Iasi
-
Iași, 루마니아, 700282
- 완전한
- Institutului Regional de Psihiatrie Socola Iasi 1
-
Iași, 루마니아, 700282
- 완전한
- Institutului Regional de Psihiatrie Socola Iasi 2
-
Oradea, 루마니아, 410169
- 모병
- Spitalul Clinic Judetean de Urgenta Oradea
-
Sibiu, 루마니아, 550082
- 완전한
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda
-
Sibiu, 루마니아, 550082
- 완전한
- Spitalul Clinic De Psihiatrie Doctor Gheorghe Preda 1
-
Sânpetru, 루마니아, 507190
- 모병
- Spitalul de Psihiatrie si Neurologie Brasov
-
-
-
-
-
Mexico City, 멕시코, 04100
- 모병
- Ketamine Mexico S de RL de C V
-
Mexico City, 멕시코, 07000
- 모병
- Gabipros SC
-
Mexico City, 멕시코, 03100
- 완전한
- Health Pharma Professional Research
-
Monterrey, 멕시코, 64710
- 모병
- Instituto de Informacion e Investigacion en Salud Mental A.C.
-
Nuevo León, 멕시코, 64460
- 모병
- Hospital Universitario Dr Jose Eleuterio Gonzalez
-
Nuevo León, 멕시코, 64620
- 완전한
- Centro de Estudios Clinicos y Especialidades Medicas S C
-
San Luis de Potosi, 멕시코, 78218
- 모병
- Hospital Lomas de San Luis Internacional
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- 완전한
- University of Alabama at Birmingham
-
-
Arizona
-
Chandler, Arizona, 미국, 85224
- 완전한
- Chandler Clinical Trials
-
Tucson, Arizona, 미국, 85724
- 모병
- University of Arizona
-
-
Arkansas
-
Bryant, Arkansas, 미국, 72022
- 모병
- SanRo Clinical Research Group LLC WCG Clinical Network
-
Little Rock, Arkansas, 미국, 72211
- 완전한
- Preferred Research Partners
-
-
California
-
Anaheim, California, 미국, 92801
- 모병
- PAMOJA Clinical Institute LLC
-
Colton, California, 미국, 92324
- 모병
- Axiom Research
-
Encino, California, 미국, 91316
- 완전한
- Elite Research Network 6
-
Glendale, California, 미국, 91206
- 모병
- Behavioral Research Specialists LLC
-
Los Alamitos, California, 미국, 90720
- 완전한
- WR PRI Los Alamitos
-
Oceanside, California, 미국, 92056
- 모병
- Excell Research Inc
-
Rancho Cucamonga, California, 미국, 91730
- 완전한
- Prospective Research Innovations Inc
-
Redlands, California, 미국, 92374
- 모병
- Anderson Clinical Research
-
San Jose, California, 미국, 95124
- 모병
- Lumos Clinical Research Center LLC
-
Santa Ana, California, 미국, 92705
- 완전한
- Syrentis Clinical Research
-
Sherman Oaks, California, 미국, 91403
- 완전한
- California Neuroscience Research
-
-
Colorado
-
Denver, Colorado, 미국, 80209
- 모병
- Mountain View Clinical Research
-
-
Connecticut
-
Farmington, Connecticut, 미국, 06030
- 모병
- UConn Health Center
-
-
Florida
-
Brandon, Florida, 미국, 33511
- 모병
- Clinical Research of Brandon
-
Hialeah, Florida, 미국, 33012
- 모집하지 않고 적극적으로
- AGA Clinical Trials
-
Hialeah, Florida, 미국, 33012
- 모집하지 않고 적극적으로
- Reliable Clinical Research
-
Homestead, Florida, 미국, 33033
- 모집하지 않고 적극적으로
- Advanced Research Institute of Miami
-
Jacksonville, Florida, 미국, 32256
- 모집하지 않고 적극적으로
- Clinical NeuroScience Solutions Inc
-
Lake City, Florida, 미국, 32055
- 완전한
- Multi Specialty Research Associates Inc
-
Largo, Florida, 미국, 33777
- 완전한
- Alcanza Clinical Research
-
Miami, Florida, 미국, 33186
- 모병
- Nuovida Research Center
-
Miami, Florida, 미국, 33126
- 모집하지 않고 적극적으로
- Pharmax Research Clinic Inc
-
Miami, Florida, 미국, 33176
- 모집하지 않고 적극적으로
- Miami Dade Medical Research Institute
-
Naples, Florida, 미국, 34105
- 완전한
- Aqualane Clinical Research
-
North Bay Village, Florida, 미국, 33141
- 완전한
- Bravo Health Care Center
-
Orlando, Florida, 미국, 32803
- 모집하지 않고 적극적으로
- Nova Psychiatry INC
-
Saint Augustine, Florida, 미국, 32086
- 완전한
- Florida Center for TMS
-
Tampa, Florida, 미국, 33613
- 완전한
- University of South Florida
-
Tampa, Florida, 미국, 33629
- 모병
- Interventional Psychiatry of Tampa Bay
-
Tampa, Florida, 미국, 33614
- 모병
- Psych Me Medical Research Inc
-
West Palm Beach, Florida, 미국, 33407
- 모병
- Health Synergy Clinical Research
-
Winter Park, Florida, 미국, 32789
- 완전한
- Conquest Research
-
-
Georgia
-
Atlanta, Georgia, 미국, 30328
- 모병
- Agile Clinical Research Trials, LLC
-
Atlanta, Georgia, 미국, 30318
- 모집하지 않고 적극적으로
- Advanced Discovery Research
-
Decatur, Georgia, 미국, 30030
- 모집하지 않고 적극적으로
- iResearch Atlanta LLC
-
Dunwoody, Georgia, 미국, 30338
- 완전한
- Peachford Hospital-Atlanta Behavorial Research
-
Savannah, Georgia, 미국, 31405
- 완전한
- iResearch Savannah
-
Snellville, Georgia, 미국, 30078
- 완전한
- Renew Health Clinical Research
-
Snellville, Georgia, 미국, 30078
- 완전한
- Accelerated Clinical Research Group LLC
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Northwestern University
-
Chicago, Illinois, 미국, 60614
- 완전한
- MetroMed Clinical Research
-
Chicago, Illinois, 미국, 60637
- 완전한
- University of Chicago Medical Center
-
Elgin, Illinois, 미국, 60123
- 완전한
- Revive Research Institute
-
Naperville, Illinois, 미국, 60563
- 모병
- Baber Research Group
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02131
- 완전한
- Boston Clinical Trials
-
Watertown, Massachusetts, 미국, 02472
- 모병
- Adams Clinical LLC
-
-
Minnesota
-
Mankato, Minnesota, 미국, 56001
- 완전한
- Mankato Clinic
-
-
Nevada
-
Las Vegas, Nevada, 미국, 89121
- 완전한
- Oasis Clinical Research LLC
-
Las Vegas, Nevada, 미국, 89119
- 완전한
- Redbird Research
-
-
New Hampshire
-
Portsmouth, New Hampshire, 미국, 03801
- 완전한
- ActivMed Practices and Research
-
-
New York
-
Brooklyn, New York, 미국, 11235
- 모병
- SPRI Clinical Trials, LLC
-
Brooklyn, New York, 미국, 11229
- 모병
- Integrative Clinical Trials LLC
-
Buffalo, New York, 미국, 14202
- 완전한
- University at Buffalo Psychiatry
-
Mount Kisco, New York, 미국, 10549
- 모병
- Bioscience Research LLC
-
New York, New York, 미국, 10017
- 모병
- Fieve Clinical Research Inc
-
New York, New York, 미국, 10022
- 완전한
- Hapworth Psychiatric Medical PLLC
-
Woodbury, New York, 미국, 11797
- 완전한
- Lucian Miron Manu MD Psychiatry PC
-
-
North Carolina
-
Hickory, North Carolina, 미국, 28601
- 완전한
- IMA Clinical Research PC 3
-
-
Ohio
-
Avon Lake, Ohio, 미국, 44012
- 완전한
- Haidar Almhana Nieding
-
Cincinnati, Ohio, 미국, 45215
- 모병
- Patient Priority Clinical Sites LLC
-
Cincinnati, Ohio, 미국, 45219
- 완전한
- University of Cincinnati College of Medicine
-
Columbus, Ohio, 미국, 43210
- 모병
- The Ohio State University
-
Middleburg Heights, Ohio, 미국, 44130
- 완전한
- North Star Medical Research
-
-
Oklahoma
-
Edmond, Oklahoma, 미국, 73013
- 모병
- Conrad Clinical Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- University of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29425
- 완전한
- Medical University of South Carolina
-
Charleston, South Carolina, 미국, 29406
- 모병
- Clinical Trials of South Carolina
-
-
Texas
-
Austin, Texas, 미국, 78712
- 완전한
- The University of Texas at Austin
-
Austin, Texas, 미국, 78759
- 완전한
- BioBehavioral Research of Austin PC
-
Bellaire, Texas, 미국, 77401
- 모병
- Houston Clinical Trials LLC
-
Dallas, Texas, 미국, 75243
- 완전한
- Relaro Medical Trials
-
Fort Worth, Texas, 미국, 76104
- 모병
- North Texas Clinical Trials
-
Garland, Texas, 미국, 75041
- 완전한
- VAST Clinical Research
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine
-
Houston, Texas, 미국, 77081
- 완전한
- DM Clinical Research
-
Stafford, Texas, 미국, 77477
- 모집하지 않고 적극적으로
- R and H Clinical Research
-
Wichita Falls, Texas, 미국, 76309
- 모병
- Grayline Research Center
-
-
Utah
-
Draper, Utah, 미국, 84020
- 완전한
- Cedar Clinical Research
-
-
Washington
-
Everett, Washington, 미국, 98201
- 모병
- Core Clinical Research
-
-
-
-
-
Burgas, 불가리아, 8001
- 모집하지 않고 적극적으로
- Mental Health Center Prof. Dr. Ivan Temkov
-
Plovdiv, 불가리아, 4002
- 모집하지 않고 적극적으로
- UMHAT 'Sveti Georgi'- Plovdiv, Psychiatry Clinic
-
Sofia, 불가리아, 1377
- 완전한
- Centre for Mental Health Prof.N.Shipkovenski EOOD
-
Sofia, 불가리아, 1113
- 모집하지 않고 적극적으로
- Medical Center St. Naum
-
Sofia, 불가리아, 1408
- 모집하지 않고 적극적으로
- DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
-
Stara Zagora, 불가리아, 6010
- 완전한
- Medical Center ZaraMed
-
Varna, 불가리아, 9020
- 모집하지 않고 적극적으로
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Brasília, 브라질, 70200 730
- 완전한
- L2IP Instituto de Pesquisas Clinicas
-
Campinas, 브라질, 13087 567
- 모집하지 않고 적극적으로
- CAEP Centro Avancado De Estudos E Pesquisas
-
Criciúma, 브라질, 88811 000
- 모집하지 않고 적극적으로
- Sociedade Literaria e Caritativa Santo Agostinho Hospital Sao Jose
-
Natal, 브라질, 59012 300
- 완전한
- Universidade Federal do Rio Grande do Norte Hospital Universitario Onofre Lopes
-
Passo Fundo, 브라질, 99010 120
- 정지된
- Instituto Mederi de Pesquisa e Saude
-
Porto Alegre, 브라질, 90619900
- 완전한
- Uniao Brasileira de Educacao e Assistencia INSCER Instituto do Cerebro do Rio Grande do Sul
-
Porto Alegre, 브라질, 90035 903
- 완전한
- Hospital De Clinicas De Porto Alegre
-
Porto Alegre, 브라질, 90430001
- 모집하지 않고 적극적으로
- NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
-
Rio de Janeiro, 브라질, 22270 060
- 모집하지 않고 적극적으로
- Ruschel Medicina e Pesquisa Clínica Ltda
-
São Bernardo do Campo, 브라질, 09726 150
- 모집하지 않고 적극적으로
- Centro Integrado Facili
-
São Paulo, 브라질, 01228 000
- 모집하지 않고 적극적으로
- CPQuali Pesquisa Clinica LTDA ME
-
São Paulo, 브라질, 01236030
- 모집하지 않고 적극적으로
- BR Trials
-
-
-
-
-
Belgrade, 세르비아, 11000
- 모집하지 않고 적극적으로
- University Clinical Center of Serbia
-
Belgrade, 세르비아, 11000
- 모집하지 않고 적극적으로
- University Clinical Hospital Center Dr Dragisa Misovic- Dedi
-
Gornja Toponica, 세르비아, 18202
- 모집하지 않고 적극적으로
- Special Hospital for Psychiatric Diseases Gornja Toponica
-
Kovin, 세르비아, 26220
- 완전한
- Special Hospital for Psychiatric Diseases Kovin
-
Novi Kneževac, 세르비아, 23330
- 완전한
- Specialized Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Lund, 스웨덴, 22222
- 모병
- ProbarE i Lund AB
-
Mölndal, 스웨덴, 43153
- 모병
- CTC GoCo
-
Stockholm, 스웨덴, 114 37
- 모병
- ProbarE i Stockholm AB
-
Uppsala, 스웨덴, 75237
- 모병
- CTC MTC Uppsala
-
-
-
-
-
Barcelona, 스페인, 08036
- 모집하지 않고 적극적으로
- Hosp Clinic de Barcelona
-
Barcelona, 스페인, 8035
- 완전한
- Hosp Univ Vall D Hebron
-
Barcelona, 스페인, 08025
- 모집하지 않고 적극적으로
- Institucion Hosp Hestia Palau
-
Bilbao, 스페인, 48013
- 완전한
- Hosp. Univ. de Basurto
-
Collado Villalba, 스페인, 28400
- 완전한
- Hosp. Gral. de Villalba
-
Madrid, 스페인, 28034
- 완전한
- Hospital Ramon y Cajal
-
Madrid, 스페인, 28031
- 모집하지 않고 적극적으로
- Hosp. Univ. Infanta Leonor
-
Madrid, 스페인, 28046
- 모집하지 않고 적극적으로
- Hosp. Univ. La Paz
-
Torrevieja, 스페인, 03186
- 완전한
- Hosp. Univ. de Torrevieja
-
-
-
-
-
Bratislava, 슬로바키아, 821 01
- 완전한
- Psychiatricka Ambulancia Mentum S.R.O.
-
Košice, 슬로바키아, 040 01
- 모병
- Univerzitna nemocnica L. Pasteura Kosice
-
Liptovský Mikuláš, 슬로바키아, 031 23
- 모병
- Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
-
Rimavská Sobota, 슬로바키아, 979 01
- 모병
- Psychiatricka Ambulancia Psycholine S.R.O.
-
Svidník, 슬로바키아, 089 01
- 모병
- Psychiatricka Ambulancia Centrum Zdravia R.B.K. S.R.O.
-
Vranov nad Topľou, 슬로바키아, 093 01
- 모병
- Crystal Comfort s.r.o.
-
-
-
-
-
Buenos Aires, 아르헨티나, C1133AAH
- 모집하지 않고 적극적으로
- Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
-
Córdoba, 아르헨티나, 5000FJF
- 모집하지 않고 적극적으로
- CEN Consultorios Especializados en Neurociencias
-
Córdoba, 아르헨티나, X5003DCE
- 모집하지 않고 적극적으로
- Instituto Medico DAMIC
-
Córdoba, 아르헨티나, X5006CBI
- 모집하지 않고 적극적으로
- Centro Medico Luquez
-
Córdoba, 아르헨티나, X5009BIN
- 모집하지 않고 적극적으로
- Sanatorio Prof Leon S Morra S A
-
La Plata, 아르헨티나, 1900
- 모집하지 않고 적극적으로
- INSA Instituto de Neurociencias San Agustín
-
Rosario, 아르헨티나, 2000
- 모집하지 않고 적극적으로
- C I A P Centro de investigacion y Asistencia en Psiquiatria
-
Santiago del Estero, 아르헨티나, 4200
- 모집하지 않고 적극적으로
- Clinica El Jardin
-
-
-
-
-
Brescia, 이탈리아, 25123
- 완전한
- Territorial Social Health Authority of the Spedali Civili of Brescia
-
Catania, 이탈리아, 95123
- 모집하지 않고 적극적으로
- Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
-
Chieti, 이탈리아, 66100
- 모집하지 않고 적극적으로
- Universita D Annunzio
-
Genova, 이탈리아, 16132
- 완전한
- IRCCS Aor San Martino IST
-
Monza, 이탈리아, 20900
- 완전한
- Fondazione IRCCS San Gerardo dei Tintori
-
Pisa, 이탈리아, 56126
- 완전한
- Azienda Ospedaliero Universitaria Pisana
-
Roma, 이탈리아, 00168
- 완전한
- Policlinico Universitario Agostino Gemelli
-
Roma, 이탈리아, 00189
- 모집하지 않고 적극적으로
- Azienda Ospedaliera Sant Andrea
-
Salerno, 이탈리아, 84020
- 완전한
- Ospedale S Francesco d Assisi
-
Siena, 이탈리아, 53100
- 모집하지 않고 적극적으로
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
-
-
-
-
Brno, 체코, 61300
- 모병
- Medipa S R O
-
Pilsen, 체코, 301 00
- 완전한
- A Shine S R O
-
Prague, 체코, 10000
- 모병
- Clintrial s r o
-
Prague, 체코, 110 00
- 모병
- Neuropsychiatrie Petrska sro
-
Prague, 체코, 16000
- 모병
- Medical Services Prague S R O
-
Prague, 체코, 12000
- 완전한
- Pragtis S R O
-
-
-
-
-
Barranquilla, 콜롬비아, 080002
- 모집하지 않고 적극적으로
- Centro de Investigaciones y Proyectos en Neurociencias CIPNA
-
Bello, 콜롬비아, 051053
- 모집하지 않고 적극적으로
- HOMO - ESE Hospital Mental de Antioquia
-
Bogotá, 콜롬비아, 111166
- 완전한
- Centro de Investigaciones del Sistema Nervioso Grupo Cisne Ltda.
-
Pereira, 콜롬비아, 660001
- 모집하지 않고 적극적으로
- Psynapsis Salud Mental S.A.
-
-
-
-
-
Ankara, 터키 (Türkiye), 06010
- 모병
- Gulhane Egitim ve Arastirma Hastanesi
-
Ankara, 터키 (Türkiye), 06800
- 완전한
- Ankara Bilkent Sehir Hastanesi
-
Ankara, 터키 (Türkiye), 06620
- 완전한
- Ankara University Medical Faculty
-
Bursa, 터키 (Türkiye), 16285
- 완전한
- Bursa High Speciality Training and Research Dortcelik Mental Hospital
-
Bursa, 터키 (Türkiye), 16059
- 완전한
- Uludag Universitesi Tıp Fakultesi Hastanesi
-
Gaziantep, 터키 (Türkiye), 27580
- 모병
- Gaziantep Universitesi Tip Fakultesi
-
Istanbul, 터키 (Türkiye), 34736
- 완전한
- Erenkoy Mental Hospital
-
Kocaeli, 터키 (Türkiye), 41001
- 모병
- Kocaeli University Medical Faculty
-
Samsun, 터키 (Türkiye), 55020
- 모병
- Liv Hospital
-
Trabzon, 터키 (Türkiye), 61080
- 완전한
- Karadeniz Teknik University Medical Faculty
-
-
-
-
-
Braga, 포르투갈, 4710 243
- 완전한
- Uls Braga - Hosp. Braga
-
Leiria, 포르투갈, 2410 197
- 완전한
- Uls Regiao Leiria - Hosp. Santo Andre
-
Lisbon, 포르투갈, 1649 035
- 완전한
- Uls Santa Maria - Hosp. Santa Maria
-
Lisbon, 포르투갈, 1349 019
- 완전한
- Uls Lisboa Ocidental - Hosp. Egas Moniz
-
Lisbon, 포르투갈, 1400 038
- 모집하지 않고 적극적으로
- Fund. Champalimaud
-
Loures, 포르투갈, 2674 514
- 모집하지 않고 적극적으로
- Uls Loures Odivelas - Hosp. Loures
-
Ponta Delgada, 포르투갈, 9500 370
- 완전한
- Hosp. Divino Espirito Santo Ponta Delgada
-
Porto, 포르투갈, 4100 180
- 모집하지 않고 적극적으로
- Hosp. Cuf Porto
-
Touguinho, 포르투갈, 4480-565
- 완전한
- Hosp. Central Trofa Saude
-
-
-
-
-
Bydgoszcz, 폴란드, 85-133
- 모병
- PROMENTE Sp. z o.o.
-
Bydgoszcz, 폴란드, 85 794
- 모병
- Osrodek Badan Klinicznych CLINSANTE S C Ewa Galczak Nowak Malgorzata Trzaska
-
Bydgoszcz, 폴란드, 85 605
- 완전한
- Centrum Medyczne Intercor Sp z o o
-
Gdansk, 폴란드, 80 283
- 모병
- Centrum Zdrowia Alcea
-
Gorlice, 폴란드, 30073
- 완전한
- Specjalistyczna Praktyka Lekarska Piotr Zalitacz
-
Grudziądz, 폴란드, 86 300
- 모병
- Przychodnie Grudziadz sp. z o.o.
-
Katowice, 폴란드, 40 514
- 모병
- Clinic BBP Sp z o o
-
Leszno, 폴란드, 64-100
- 모병
- Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
-
Poznan, 폴란드, 60 192
- 모병
- Praktyka Lekarska dr n med Malgorzata Wojtanowska Bogacka
-
Warsaw, 폴란드, 00-774
- 모병
- Szpital Nowowiejski Osrodek Badan Klinicznych
-
Warsaw, 폴란드, 02-172
- 완전한
- MTZ Clinical Research Powered by Pratia
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Participants in part 1 and direct enrollers to part 2:
- Meet DSM-5 MDD, without psychotic features based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60
- Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. An inadequate response is defined as less than (<) 50% reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms other than insomnia present, and overall good tolerability, as assessed by the MGH-ATRQ, and this must include the participant's current antidepressant treatment
- Is receiving and tolerating well any one of the following SSRI or SNRI for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at therapeutic dose level) for at least 6 weeks
- Having a major depressive episode of at least moderate severity, as assessed with 17-item Hamilton Depression Rating Scale, implemented through the Structured Interview Guide (SIGH-D) in a blinded manner at screening and must not demonstrate a clinically significant improvement from the beginning to end of screening.
Participants entering after completing part 1:
- Must have completed Part 1 DB treatment phase
- Can consistently tolerate study drug (at the end of Part 1), and there is no additional safety risk for the participant if they proceed to Part 2
- Was able to consistently follow the study procedures in Part 1 as judged by the investigator.
- Must be medically stable based on clinical laboratory tests
Exclusion Criteria:
- Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders and uncontrolled Type 1 or Type 2 diabetes mellitus
- Has a history of narcolepsy and seizures
- Has current signs/symptoms of hypothyroidism or hyperthyroidism
- Participants taking thyroid supplementation for antidepressant purposes
- Has Cushing's disease, Addison's disease, primary amenorrhea, or other evidence of significant medical disorders of the HPA axis
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Part 1: Seltorexant
Participants will receive seltorexant orally once daily for 6 weeks during the double-blind (DB) treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant throughout the study. |
Seltorexant will be administered orally.
다른 이름들:
SSRI/SNRI will be administered orally. |
|
위약 비교기: Part 1: Placebo
Participants will receive matching placebo orally once daily for 6 weeks during the DB treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
SSRI/SNRI will be administered orally. Matching Placebo tablets will be administered orally. |
|
실험적: Part 2: Open Label (OL) Seltorexant
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. In Part 2 open-label phases (induction and stabilization) all participants (newly enrolled direct entry participants and Part 1 roll-over participants) will receive seltorexant orally in addition to their background SSRI/SNRI treatment. |
Seltorexant will be administered orally.
다른 이름들:
SSRI/SNRI will be administered orally. |
|
실험적: Part 2: DB Seltorexant
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phase will receive treatment with seltorexant orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
Seltorexant will be administered orally.
다른 이름들:
SSRI/SNRI will be administered orally. |
|
위약 비교기: Part 2: DB Placebo
All participants who complete Part 1, and who meet eligibility criteria for Part 2, as well as direct entry participants, will enter Part 2 of the study. Participants who achieve a stable response during the open-label phases will receive treatment with matching placebo orally once daily during DB Maintenance Phase in Part 2 of the study. Participants will continue to take their single baseline SSRI/SNRI antidepressant throughout the study. |
SSRI/SNRI will be administered orally. Matching Placebo tablets will be administered orally. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43
기간: Baseline, Day 43
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
Baseline, Day 43
|
|
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Response
기간: Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)
|
Stable response is defined as a greater than equal to (>=) 50 percent (%) reduction in the MADRS total score for the last 3 consecutive visits of the OL stabilization Phase, as assessed by the site investigator. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve a stable response at the end of OL seltorexant treatment will be reported. |
Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Part 1: Change from Baseline in the MADRS Without Sleep Item (MADRS-WOSI) Total Score at Day 43
기간: Baseline, Day 43
|
MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form 8a T-score at Day 43
기간: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in the MADRS-6 Total Score at Day 43
기간: Baseline, Day 43
|
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of major depressive disorder (MDD) symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms). |
Baseline, Day 43
|
|
Part 1: Percentage of Participants with Response on Depressive Symptoms Scale Based on Montgomery-Asberg Depression Rating Scale (MADRS) Total score From Baseline to Day 43
기간: From Baseline to Day 43
|
Responders are defined as participants with >= 50 percent improvement in the MADRS total score from baseline to Day 43. |
From Baseline to Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (4a) T-score at Day 43
기간: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
기간: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 1: Change from Baseline in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score at Day 43
기간: Baseline, Day 43
|
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. |
Baseline, Day 43
|
|
Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Remission
기간: Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
|
Stable remission is defined as MADRS total score less than or equal to (<=)10 and CGI-S <= 2 for at least 4 consecutive weeks of the OL stabilization Phase. Time from randomization to the first relapse during the DB maintenance phase in participants who achieve stable remission at the end of the OL seltorexant treatment will be reported. |
Time from randomization to the first relapse during the maintenance phase (up to 2 years and 10 months)
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (8a) T-Score
기간: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 8-item form, the lowest possible raw score is 8; the highest possible raw score is 40. Higher overall score indicates more sleep disturbance. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in Sleep Disturbance Using the PROMIS-SD Short Form (4a) T-Score
기간: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 4-item short form will be used in this study, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 4-item form, the lowest possible raw score is 4; the highest possible raw score is 20. Higher overall score indicates more sleep disturbance. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form (10a) T-score at Day 43
기간: Baseline, Day 43
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The full PROMIS-SD includes 27 items with each item based on a 7-day recall period and assessed on a 5 level Likert-type scale. The 10-item short form will be used, in which responses are scored 1 to 5 for each item. T-score for the PROMIS-SD scales represent the value obtained after using a conversion table to convert the total raw score. To find the total raw score for a short form with all questions answered, sum the values of the response to each question. For example, for the adult 10-item form, the lowest possible raw score is 10; the highest possible raw score is 50. Higher overall score indicates more sleep disturbance. |
Baseline, Day 43
|
|
Part 2: Change from Baseline to Endpoint of the DB Maintenance Phase in MADRS Total Score
기간: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Part 2: Change from Baseline to Endpoint of DB Maintenance Phase in PHQ-9 Score
기간: From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
|
The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the DSM-5 MDD criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. |
From Baseline (Day 1 in the DB Treatment Maintenance Phase) Until End Point of the DB Maintenance Phase (that is, up to Day 337)
|
|
Change From Baseline to Endpoint of the DB Maintenance Phase in the MADRS-6 score
기간: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
The MADRS-6 scale is a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale is a subset of the MADRS -10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Scores range from 0 (no apparent symptoms) to 36 (most severe symptoms). |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
|
Change from Baseline to Endpoint of the DB Maintenance Phase in the MADRS symptoms other than insomnia MADRS Without Sleep Item (MADRS-WOSI)
기간: From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
MADRS-WOSI considered 9 of the 10 MADRS items, excluding "reduced sleep" item. The total score ranged from 0 to 54, with higher scores corresponding to greater symptom severity. |
From Baseline (Day 1 in the DB treatment maintenance Phase) until end point of the DB maintenance phase (that is up to Day 337)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trail, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 42847922MDD3003
- 42847922MDD3003 (기타 식별자: Janssen Research & Development, LLC)
- 2023-509070-36-00 (레지스트리 식별자: EUCT number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www janssen, com/clinical-trialsitransparency. As noted on this site, requests for access to the study data can be submitted through 'Yale Open Data Access (YODA) Project site at yoda yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .